Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Circulating Tumor DNA As a Biomarker for Molecular Residual Disease Assessment in Patients with Diffuse Large B-Cell Lymphoma

Mayur Narkhede, Sarah Tomassetti, Madiha Iqbal, Katie LaBarbera, Hayley Widden, Ryan Benrud, Richa Rathore, Ekaterina Kalashnikova, Allyson Koyen Malashevich, Minetta Liu, Alexey Aleshin

Blood (2022) 140 (Supplement 1): 11884–11886.

https://doi.org/10.1182/blood-2022-169656

Published: 2022

Journal Articles

MDS and MDS/MPN Genomic Subgroups Demonstrate Differential E x Vivo Drug Sensitivity

Michael A Spinner, Steven A Schaffert, Henning Stehr, Marianne T Santaguida, Ryosuke Kita, Alexey Aleshin, James L Zehnder, Peter L. Greenberg

Blood (2021) 138 (Supplement 1): 4645.

https://doi.org/10.1182/blood-2021-152103

Published: 2021

Journal Articles

Correlating Clinical and Genomic Features with E x Vivo Drug Sensitivity in Patients with Myelodysplastic Syndromes and Related Myeloid Neoplasms

Michael A Spinner, MD, Steven A Schaffert, PhD, Alexey Aleshin, MD MBA, Marianne T Santaguida, PhD, Hiroomi Tada, MDPhD, Peter L. Greenberg

Blood (2020) 136 (Supplement 1): 19–20.

https://doi.org/10.1182/blood-2020-140095

Published: 2020

Journal Articles

A Feasibility Study of Biologically Focused Therapy for Myelodysplastic Syndrome Patients Refractory to Hypomethylating Agents

Michael A Spinner, Alexey Aleshin, MD MBA, Marianne A Santaguida, PhD, Steven A Schaffert, PhD, Taher Abbasi, MS, MBA, Jeffrey N Sanders, A Scott Patterson, MA, Diane Heiser, PhD, James L Zehnder, Peter L Greenberg, MD

Blood (2019) 134 (Supplement_1): 4239.

https://doi.org/10.1182/blood-2019-129473

Published: 2019

Journal Articles

Ex Vivo Drug Response Profiling Defines Novel Drug Sensitivity Patterns for Predicting Clinical Therapeutic Responses in Myeloid Neoplasms

Alexey Aleshin, MDMBA, Marianne A Santaguida, PhD, Michael A Spinner, MD, Jeffrey N Sanders, A Scott Patterson, Christos Gekas, PhD, Steven Schaffert, PhD, Peter L Greenberg, MD

Blood (2018) 132 (Supplement 1): 4356.

https://doi.org/10.1182/blood-2018-99-120146

Published: 2018

Journal Articles

Single-Cell Mutational Profiling Describes the Molecular Heterogeneity of Clonal Evolution in MDS during Therapy and Relapse

Alexey Aleshin, MD MBA, Robert Durruthy-Durruthy, PhD, Bruno C. Medeiros, MD, Dennis J. Eastburn, PhD, Peter L Greenberg, MD

Blood (2018) 132 (Supplement 1): 5503.

https://doi.org/10.1182/blood-2018-99-120368

Published: 2018

Journal Articles

Single-Cell Mutational Profiling of Clonal Evolution in De Novo AML during Therapy and Relapse

Alexey Aleshin, MD MBA, Robert Durruthy-Durruthy, PhD, M. Ryan Corces, PhD, Melissa Stafford, Michaela Liedtke, MD, Bruno C. Medeiros, MD, Dennis J. Eastburn, PhD, Ravindra Majeti, MD PhD

Blood (2018) 132 (Supplement 1): 1469.

https://doi.org/10.1182/blood-2018-99-118089

Published: 2018

NARROW

Circulating Tumor DNA As a Biomarker for Molecular Residual Disease Assessment in Patients with Diffuse Large B-Cell Lymphoma

MDS and MDS/MPN Genomic Subgroups Demonstrate Differential E x Vivo Drug Sensitivity

Correlating Clinical and Genomic Features with E x Vivo Drug Sensitivity in Patients with Myelodysplastic Syndromes and Related Myeloid Neoplasms

A Feasibility Study of Biologically Focused Therapy for Myelodysplastic Syndrome Patients Refractory to Hypomethylating Agents

Ex Vivo Drug Response Profiling Defines Novel Drug Sensitivity Patterns for Predicting Clinical Therapeutic Responses in Myeloid Neoplasms

Single-Cell Mutational Profiling Describes the Molecular Heterogeneity of Clonal Evolution in MDS during Therapy and Relapse

Single-Cell Mutational Profiling of Clonal Evolution in De Novo AML during Therapy and Relapse

Email alerts

ASH Publications

American Society of Hematology

Circulating Tumor DNA As a Biomarker for Molecular Residual Disease Assessment in Patients with Diffuse Large B-Cell Lymphoma

MDS and MDS/MPN Genomic Subgroups Demonstrate Differential E x Vivo Drug Sensitivity

Correlating Clinical and Genomic Features with E x Vivo Drug Sensitivity in Patients with Myelodysplastic Syndromes and Related Myeloid Neoplasms

A Feasibility Study of Biologically Focused Therapy for Myelodysplastic Syndrome Patients Refractory to Hypomethylating Agents

Ex Vivo Drug Response Profiling Defines Novel Drug Sensitivity Patterns for Predicting Clinical Therapeutic Responses in Myeloid Neoplasms

Single-Cell Mutational Profiling Describes the Molecular Heterogeneity of Clonal Evolution in MDS during Therapy and Relapse

Single-Cell Mutational Profiling of Clonal Evolution in De Novo AML during Therapy and Relapse

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only